Table 4.

Survival outcomes by FcγRIIa and FcγRIIIa polymorphisms and treatment

5-y PFS (95% CI)Treatment by FcγR SNP interaction5-y DPFS (95% CI)Treatment by FcγR SNP interaction5-y OS (95% CI)Treatment by FcγR SNP interaction
FcγR polymorphismCAPOX (n = 54)CAPOX-C (n = 51)PCAPOX (n = 54)CAPOX-C (n = 51)PCAPOX (n = 54)CAPOX-C (n = 51)P
HH61.5 (35.0–88.0)45.5 (16.1–74.9)0.08880.0 (55.3–100)45.5 (16.1–74.9)0.05169.2 (44.1–94.3)63.6 (35.2–92.0)0.186
HR45.9 (26.5–65.3)80.0 (64.3–95.7)63.5 (44.3–82.7)83.5 (68.6–98.4)50.2 (30.9–69.4)88.0 (75.3–100)
RR69.2 (44.1–94.3)60.0 (35.3–84.7)81.8 (59.1–100)64.3 (39.2–89.4)69.2 (44.1–94.3)72.7 (49.8–95.6)
HH61.5 (35.0–88.0)45.5 (16.1–74.9)0.09680.0 (55.3–100)45.5 (16.1–74.9)0.04269.2 (44.1–94.3)63.6 (35.2–92.0)0.232
HR/RR53.9 (38.2–69.6)72.5 (58.6–86.4)69.2 (53.9–84.5)76.4 (62.9–89.9)56.6 (41.1–72.1)82.4 (70.6–94.2)
VV42.9 (6.3–79.6)20.0 (0–55.1)0.35680.0 (44.9–100)33.3 (0–86.6)0.41642.9 (6.2–79.6)60.0 (17.1–100)0.880
VF50.0 (30.0–70.0)62.5 (43.1–81.9)70.7 (50.9–90.5)62.5 (43.1–81.9)58.3 (38.5–78.1)74.2 (56.4–92.0)
FF67.3 (47.3–87.3)81.8 (65.7–97.9)70.8 (51.0–90.6)81.8 (65.7–97.9)67.0 (47.0–86.9)86.4 (72.1–100)
VV42.9 (6.3–79.6)20.0 (0–55.1)0.15780.0 (44.9–100)33.3 (0–86.6)0.27842.9 (6.2–79.6)60.0 (17.1–100)0.666
VF/FF57.9 (43.4–72.4)71.7 (58.8–84.6)70.7 (56.8–84.6)71.7 (58.8–84.6)62.4 (48.3–76.5)80.2 (68.6–91.8)
HH and/or VV56.3 (32.0–80.6)35.7 (10.6–60.8)0.01775.5 (51.4–99.6)42.0 (14.0–70.0)0.03262.5 (38.8–86.2)57.1 (31.2–82.9)0.080
R and F55.7 (38.8–72.6)78.4 (65.1–91.7)69.8 (54.1–85.5)78.4 (65.1–91.7)58.5 (42.4–74.6)86.4 (75.2–97.6)